Replaced Notes. If a Note is replaced pursuant to Section 2.13, then such Note will cease to be outstanding at the time of its replacement, unless the Trustee and the Company receive proof reasonably satisfactory to them that such Note is held by a “bona fide purchaser” under applicable law.
Appears in 168 contracts
Sources: Indenture (Coinbase Global, Inc.), Indenture (Coinbase Global, Inc.), Indenture (DeFi Development Corp.)
Replaced Notes. If a Note is replaced pursuant to Section 2.132.12, then such Note will cease to be outstanding at the time of its replacement, unless the Trustee and the Company receive proof reasonably satisfactory to them that such Note is held by a “bona fide purchaser” under applicable law.
Appears in 43 contracts
Sources: Indenture (Beauty Health Co), Indenture (Eos Energy Enterprises, Inc.), Indenture (Trump Media & Technology Group Corp.)
Replaced Notes. If a Note is replaced pursuant to Section 2.133.07, then such Note will cease to be outstanding at the time of its replacement, unless the Trustee and the Company receive receives proof reasonably satisfactory to them it that such Note is held by a “bona fide purchaser” purchaser under applicable law.
Appears in 4 contracts
Sources: Securities Purchase Agreement (Graf Acquisition Corp. IV), Senior Convertible Note Purchase Agreement (Scynexis Inc), Senior Convertible Note Purchase Agreement (Scynexis Inc)
Replaced Notes. If a Note is replaced pursuant to Section 2.13, then such Note will cease to be outstanding at the time of its replacement, unless the Trustee and the Company receive proof reasonably satisfactory to them that such Note is held by a “bona fide protected purchaser” under applicable law.
Appears in 4 contracts
Sources: Indenture (Maxeon Solar Technologies, Ltd.), Indenture (Maxeon Solar Technologies, Ltd.), Indenture (Maxeon Rooster HoldCo, Ltd.)
Replaced Notes. If a Note is replaced pursuant to Section 2.132.07 of the Base Indenture, then such Note will cease to be outstanding at the time of its replacement, unless the Trustee and the Company receive proof reasonably satisfactory to them that such Note is held by a “bona fide purchaser” under applicable law.
Appears in 3 contracts
Sources: First Supplemental Indenture (Celcuity Inc.), First Supplemental Indenture (Cytokinetics Inc), First Supplemental Indenture (Retrophin, Inc.)
Replaced Notes. If a Note is replaced pursuant to Section 2.132.8 of the Base Indenture, then such Note will cease to be outstanding at the time of its replacement, unless the Trustee and the Company receive proof reasonably satisfactory to them that such Note is held by a “bona fide purchaser” under applicable law.
Appears in 3 contracts
Sources: Second Supplemental Indenture (Verastem, Inc.), First Supplemental Indenture (Mesa Laboratories Inc /Co), First Supplemental Indenture (Verastem, Inc.)
Replaced Notes. If a Note is replaced pursuant to Section 2.132.07 of the Base Indenture, then such Note will cease to be outstanding Outstanding at the time of its replacement, unless the Trustee and the Company receive proof reasonably satisfactory to them that such Note is held by a “bona fide purchaser” under applicable law.
Appears in 2 contracts
Sources: First Supplemental Indenture (Tilray Brands, Inc.), First Supplemental Indenture (Inseego Corp.)
Replaced Notes. If a Note is replaced pursuant to Section 2.13Section 2.12, then such Note will cease to be outstanding at the time of its replacement, unless the Trustee and the Company receive proof reasonably satisfactory to them that such Note is held by a “bona fide purchaser” under applicable law.
Appears in 2 contracts
Sources: First Supplemental Indenture (AeroVironment Inc), Indenture (Lucid Group, Inc.)
Replaced Notes. If a Note is replaced pursuant to Section Section 2.13, then such Note will cease to be outstanding at the time of its replacement, unless the Trustee and the Company receive proof reasonably satisfactory to them that such Note is held by a “bona fide purchaser” under applicable law.
Appears in 2 contracts
Sources: Indenture (Ani Pharmaceuticals Inc), Indenture (Biora Therapeutics, Inc.)
Replaced Notes. If a Note is replaced pursuant to Section 2.13, then such Note will cease to be outstanding at the time of its replacement, unless the Trustee and the Company receive receives proof reasonably satisfactory to them that such Note is held by a “bona fide purchaser” under applicable law.
Appears in 1 contract
Sources: Note Subscription Agreement (Marti Technologies, Inc.)
Replaced Notes. If a Note is replaced pursuant to Section 2.133.6 of the Base Indenture, then such Note will cease to be outstanding at the time of its replacement, unless the Trustee and the Company receive proof reasonably satisfactory to them that such Note is held by a “bona fide purchaser” under applicable law.
Appears in 1 contract
Sources: Ninth Supplemental Indenture (Weatherford International PLC)
Replaced Notes. If a Note is replaced pursuant to Section 2.133.06(a), then such Note will cease to be outstanding at the time of its replacement, unless the Trustee and the Company receive receives proof reasonably satisfactory to them it that such Note is held by a “bona fide purchaser” purchaser under applicable law.
Appears in 1 contract
Sources: Senior Convertible Note Purchase Agreement (Scynexis Inc)
Replaced Notes. If a Note is replaced pursuant to Section 2.132.16, then such Note will cease to be outstanding at the time of its replacement, unless the Trustee and the Company receive proof reasonably satisfactory to them that such Note is held by a “bona fide purchaser” under applicable law.
Appears in 1 contract
Sources: Indenture (Verastem, Inc.)